Research and development agenda defined and research coordinated in line with public health priorities The Secretariat will step up its leadership by: 
ensuring that the limited funding that is available is directed to research priorities and innovative new products that will provide significant added value over standard of care;
enabling the rapid introduction and roll-out of newly developed paediatric medicines through its participation in the Global Accelerator for Paediatric Formulations network;
promoting close collaboration with public?private partnerships and stimulating innovative funding for globally important research and development;
supporting the scale-up of research and development in areas where there is a compelling unmet public health need for new products;
facilitating the most expeditious development of products that address the greatest and most urgent public health needs by implementing a standardized process for target product profile development in order to keep product developers, regulatory agencies, procurement agencies and funders informed about research and development and public health priorities; 
identifying research and development gaps and promoting research and development coordination to catalyse public and private funding towards identified research priorities; 
supporting new research and development strategies and initiatives;
participating in the advisory bodies of the Global Antibiotic Research and Development Partnership, the newly established AMR Action Fund and the Global Knowledge Centre for Antimicrobial Resistance Research and Development, among other entities; 
focusing on specific vulnerable groups, taking into account gender issues and human rights and working towards equitable access to treatment for antimicrobial resistance; 
initiating processes to identify priority formulations to be developed for various diseases;
continuing to build and expand on WHO?s convening role in the area of paediatric drug optimization across disease areas, including activities to prioritize, accelerate and support research and development for missing formulations to prevent and treat those diseases that mostly affect children globally; and
championing research and development that benefits vulnerable populations and promotes health equity.
The Secretariat will support countries to: 
increase the integration and coordination among centralized data repositories to share information on research and development pipelines, clinical trials data and health research system indicators globally; 
enhance national and regional research and development capacity to develop priority, essential health products and utilize target product profiles in the development of new products to address public health needs; and
rapidly approve, introduce and roll out newly developed paediatric formulations, including support to strengthen post-marketing surveillance and pharmacovigilance specific to the paediatric population.
In producing global public health goods, the Secretariat will:
create effective cross-organizational mechanisms for research and development, including by establishing research and development networks;
develop a joint scientific advice procedure, whereby product developers may approach the Secretariat for advice on prequalification in order to enhance the accelerated development of products that meet the criteria for likely public health value; 
update the global priority list of antimicrobial-resistant bacteria and fungal pathogens of public importance; and
provide regular reviews and assessments of the development pipeline for treatments and vaccines in order to encourage continued investment in new strategies to promote the development of new antibacterial treatments and antifungal treatments and diagnostics. Improved access to essential medicines, vaccines, diagnostics and devices for primary health care